President Trump has made promises to lower prescription drug prices a central argument in his reelection campaign. A key part of that effort is a recently signed executive order to ensure a “most-favored-nation price” for prescription drugs. Essentially, this means that the lowest price, after certain adjustments for market conditions, for drugs sold in developmentally similar nations would be what Medicare will pay under its Parts B and D prescription drug programs.
